Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
Geregistreerd in mei 2012
5 foto's en video's Foto's en video's

Tweets

Je hebt @AblynxABLX geblokkeerd

Weet je zeker dat je deze Tweets wilt bekijken? @AblynxABLX wordt niet gedeblokkeerd door Tweets te bekijken.

  1. heeft geretweet
    26 jul.

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 retweets 4 vind-ik-leuks
  2. heeft geretweet
    20 jul.

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 retweets 7 vind-ik-leuks
  3. 20 jul.

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    1 antwoord 9 retweets 14 vind-ik-leuks
  4. 27 jun.

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 retweets 16 vind-ik-leuks
  5. 26 jun.

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 retweets 6 vind-ik-leuks
  6. 29 mei

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 retweets 9 vind-ik-leuks
  7. 22 mei

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 retweets 12 vind-ik-leuks
  8. 18 mei

    Meet our experts and recruiters (booth 99) @

    2 vind-ik-leuks
  9. 11 mei

    Ablynx zit op schema via

    4 retweets 6 vind-ik-leuks
  10. 11 mei

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 retweets 4 vind-ik-leuks
  11. 10 mei

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 retweets 7 vind-ik-leuks
  12. 2 mei

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 retweets 6 vind-ik-leuks
  13. 7 apr.

    Annual Report 2016 is available online - view via

    1 retweet 4 vind-ik-leuks
  14. 7 apr.

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    1 retweet 4 vind-ik-leuks
  15. heeft geretweet
    6 mrt.

    Compelling data for developed psoriasis nanobody in collaboration

    3 retweets 2 vind-ik-leuks
  16. heeft geretweet
    28 feb.

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 antwoorden 51 retweets 103 vind-ik-leuks
  17. heeft geretweet
    24 feb.

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    1 retweet 1 vind-ik-leuk
  18. 23 feb.

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 retweets 3 vind-ik-leuks
  19. 9 feb.

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 retweets 2 vind-ik-leuks
  20. 6 feb.

    Ablynx files caplacizumab for ultra rare blood disorder
    6 retweets 9 vind-ik-leuks

@AblynxABLX heeft nog niet getweet.

Het laden lijkt wat langer te duren.

Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.

    Je bent misschien ook geïnteresseerd in

    ·